US4797473A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies to unreduced, nonenzymatically-glycated proteins
Assignee: University of Minnesota System
•
Filing: 1986-06-25
•
Granted: 1989-01-10
•
Expires: 2006-06-25
Abstract
Abstract A hybridoma is provided which yields a monoclonal antibody which binds to an epitope on an unreduced, nonenzymatically-glycated plasma protein, and which is substantially free of cross-reactivity with the corresponding non-glycated plasma protein.
Inventors
- 👤 Joseph F. Tarsio
- 👤 Leo T. Furcht
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:25
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
111 words
A hybridoma produced by a process comprising: (a) immunizing mammalian B lymphocytes with an effective amount of unreduced, nonenzymatically-glycated protein selected from the group consisting of total serum protein and laminin; (b) recovering the immunized B lymphocytes; (c) fusing said recovered B lymphocytes with malignant mammalian B lymphocytes to produce hybridomas; (d) selecting from said hybridomas a hybridoma which produces a monoclonal antibody which binds to an epitope on an unreduced, nonenzymatically-glycated protein, selected from the group consisting of total serum protein, fibronectin, transferrin and laminin, and which is substantially free of crossreactivity with the corresponding nonglycated protein when tested by enzyme-linked immunosorbent assay; and (e) clonally expanding said selected hybridomas.
Claim 2
Dependent Claim
111 words
A hybridoma produced by a process comprising: (a) immunizing mammalian B lymphocytes with an effective amount of unreduced, nonenzymatically-glycated protein selected from the group consisting of total serum protein and laminin; (b) recovering the immunized B lymphocytes; (c) fusing said recovered B lymphocytes with malignant mammalian B lymphocytes to produce hybridomas; (d) selecting from said hybridomas a hybridoma which produces a monoclonal antibody which binds to an epitope on an unreduced, nonenzymatically-glycated protein, selected from the group consisting of total serum protein, fibronectin, transferrin and laminin, and which is substantially free of crossreactivity with the corresponding nonglycated protein when tested by enzyme-linked immunosorbent assay; and (e) clonally expanding said selected hybridomas.
Claim 3
Dependent Claim
19 words
The hybridoma of claim 1 wherein the immunized B lymphocytes are recovered from the spleens of an immunized mammal.
Claim 4
Dependent Claim
12 words
The hybridoma of claim 2 wherein the immunized mammal is a mouse.
Claim 5
Dependent Claim
15 words
The hybridoma of claim 2 wherein the B lymphocytes are fused with murine myeloma cells.
Claim 6
Dependent Claim
14 words
The hybridoma of claim 1 wherein the ammal is immunized with a murine protein.
Claim 7
Dependent Claim
24 words
The hybridoma of claim 1 wherein the mammal is immunized with an amount of unreduced, nonenzymatically-glycated total serum protein effective to immunize said mammal.
Claim 8
Dependent Claim
14 words
The hybridoma of claim 6 wherein the mammal is immunized with a murine protein.
Claim 9
Independent Claim
102 words
A method of producing a population of hybridomas comprising: (a) immunizing mammalian B lymphocytes with an effective amount of an unreduced, nonenzymatically-glycated protein selected from the group consisting of total serum protein and laminin; (b) recovering the immunized B lymphocytes; (c) fusing said recovered B lymphocytes with malignant mammalian B lymphocytes to produce hybridomas; (d) selecting from said hybridomas a hybridoma which produces a monoclonal antibody which binds to an epitope on an unreduced, nonenzymatically-glycated plasma protein, and which is substantially free of cross-reactivity with the corresponding nonglycated plasma protein as tested by enzyme-linked immunosorbent assay; (e) clonally expanding said selected hybridomas.
Claim 10
Independent Claim
102 words
A method of producing a population of hybridomas comprising: (a) immunizing mammalian B lymphocytes with an effective amount of an unreduced, nonenzymatically-glycated protein selected from the group consisting of total serum protein and laminin; (b) recovering the immunized B lymphocytes; (c) fusing said recovered B lymphocytes with malignant mammalian B lymphocytes to produce hybridomas; (d) selecting from said hybridomas a hybridoma which produces a monoclonal antibody which binds to an epitope on an unreduced, nonenzymatically-glycated plasma protein, and which is substantially free of cross-reactivity with the corresponding nonglycated plasma protein as tested by enzyme-linked immunosorbent assay; (e) clonally expanding said selected hybridomas.
Claim 11
Dependent Claim
19 words
The method of claim 8 wherein the immunized B lymphocytes are recovered from the spleens of an immunized mammal.
Claim 12
Dependent Claim
12 words
The method of claim 8 wherein the immunized mammal is a mouse.
Claim 13
Dependent Claim
16 words
The method of claim 8 wherein the immunized B lymphocytes are fused with murine myeloma cells.
Claim 14
Dependent Claim
14 words
The method of claim 8 wherein the mammal is immunized with a murine protein.
Claim 15
Dependent Claim
24 words
The method of claim 8 wherein the mammal is immunized with an amount of unreduced, nonenzymatically-glycated total serum protein effective to immunize said mammal.
Claim 16
Dependent Claim
13 words
The method of claim 13 wherein the mammal is immunized with murine protein.
Claim 17
Dependent Claim
19 words
The method of claim 8 wherein the monoclonal antibody binds to an epitope on an unreduced, nonenzymatically-glycated human protein.
Claim 18
Dependent Claim
66 words
A monoclonal antibody which binds to an epitope on an unreduced, nonenzymatically-glycated protein selected from the group consisting of total serum protein, fibronectin, transferrin and laminin, wherein said glycated protein comprises glucose attached to an epsilon-amino group of a lysine residue in the polypeptide chain of the protein, and which antibody does not substantially cross-react with the corresponding non-glycated protein as tested by enzyme-linked immunosorbent assay.
Claim 19
Dependent Claim
66 words
A monoclonal antibody which binds to an epitope on an unreduced, nonenzymatically-glycated protein selected from the group consisting of total serum protein, fibronectin, transferrin and laminin, wherein said glycated protein comprises glucose attached to an epsilon-amino group of a lysine residue in the polypeptide chain of the protein, and which antibody does not substantially cross-react with the corresponding non-glycated protein as tested by enzyme-linked immunosorbent assay.
Claim 20
Dependent Claim
12 words
The monoclonal antibody of claim 16 which is a murine monoclonal antibody.
Claim 21
Dependent Claim
14 words
The monoclonal antibody of claim 16 wherein the glycated protein is a human protein.
Claim 22
Independent Claim
64 words
A method for detecting the presence of an unreduced, nonenzymatically-glycated protein in a tissue sample or a sample of a physiological fluid, which comprises reacting said sample with the monoclonal antibody of claims 1 or 16 and determining the presence of the protein-antibody complexes by reacting the complex with an antibody against said monoclonal antibody, wherein said antibody is bound to a detectable label.
Claim 23
Dependent Claim
10 words
The method of claim 19 wherein said fluid is blood.
Claim 24
Dependent Claim
10 words
The method of claim 19 wherein said fluid is urine.
Claim 25
Dependent Claim
10 words
The method of claim 19 wherein said fluid is saliva.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-01-10 | 1992-07-11 | 1993-01-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-01-10 | 1996-07-11 | 1997-01-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-01-10 | 2000-07-11 | 2001-01-10 | $7700.00 | Window Closed / Lapsed |